{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:31Z","timestamp":1787030131034,"version":"build-2736575974"},"reference-count":64,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Grants Council of the Hong Kong Special Administrative Region","award":["UGC\/FDS17\/M07\/22"],"award-info":[{"award-number":["UGC\/FDS17\/M07\/22"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Epstein\u2013Barr virus (EBV), a double-stranded DNA virus, is implicated in nasopharyngeal carcinoma (NPC), with particularly high incidence in regions such as southern China and Hong Kong. Although NPC is typically treated with radio- and chemotherapy, outcomes remain poor for advanced-stage diagnoses, highlighting the need for targeted therapies. This study explores the potential of CRISPR\/CRISPR-associated protein 13 (Cas13) technology to target essential EBV RNA in NPC cells. Previous research demonstrated that CRISPR\/Cas9 could partially reduce EBV load, but suppression was incomplete. Here, the combination of CRISPR\/Cas13 with CRISPR\/Cas9 shows enhanced viral clearance. Long-term EBNA1 suppression via CRISPR\/Cas13 reduced the EBV genome, improved CRISPR\/Cas9 effectiveness, and identified suitable AAV serotypes for delivery. Furthermore, cotreatment increased NPC cell sensitivity to 5-fluorouracil and cisplatin. These findings underscore the potential of CRISPR\/Cas13 as an anti-EBV therapeutic approach, effectively targeting latent EBV transcripts and complementing existing treatments. The study suggests a promising new direction for developing anti-EBV strategies, potentially benefiting therapies for NPC and other EBV-associated malignancies.<\/jats:p>","DOI":"10.3390\/v17070899","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:55:43Z","timestamp":1751442943000},"page":"899","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CRISPR\/Cas13-Mediated Inhibition of EBNA1 for Suppression of Epstein\u2013Barr Virus Transcripts and DNA Load in Nasopharyngeal Carcinoma Cells"],"prefix":"10.3390","volume":"17","author":[{"given":"Lin","family":"Lin","sequence":"first","affiliation":[{"name":"School of Nursing, Tung Wah College, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Yin","family":"Lui","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-7926","authenticated-orcid":false,"given":"Chon Phin","family":"Ong","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel Yin-Chun","family":"Yau","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Tung Wah College, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-3530","authenticated-orcid":false,"given":"Dong-Yan","family":"Jin","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-7709","authenticated-orcid":false,"given":"Kit-San","family":"Yuen","sequence":"additional","affiliation":[{"name":"School of Nursing, Tung Wah College, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.coviro.2012.07.001","article-title":"Novel Mechanisms of EBV-Induced Oncogenesis","volume":"2","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1044579X02000858","article-title":"Epidemiology of Nasopharyngeal Carcinoma","volume":"12","author":"Yu","year":"2002","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0092-8674(86)90803-2","article-title":"The Structure of the Termini of the Epstein-Barr Virus as a Marker of Clonal Cellular Proliferation","volume":"47","author":"Flynn","year":"1986","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective","volume":"33","author":"Lee","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal Carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"ref_6","first-page":"549","article-title":"EBV Infection and Persistence in Nasopharyngeal Epithelial Cells","volume":"33","author":"Tsang","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sugiokto, F.G., and Li, R. (2025). Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges. Viruses, 17.","DOI":"10.3390\/v17010110"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1039\/C4CC01589D","article-title":"EBNA1-Specific Luminescent Small Molecules for the Imaging and Inhibition of Latent EBV-Infected Tumor Cells","volume":"50","author":"Jiang","year":"2014","journal-title":"Chem. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e70168","DOI":"10.1002\/jmv.70168","article-title":"USP7 Inhibitors Destabilize EBNA1 and Suppress Epstein-Barr Virus Tumorigenesis","volume":"97","author":"Chen","year":"2025","journal-title":"J. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dheekollu, J., Wiedmer, A., Soldan, S.S., Castro- Mu\u00f1oz, L.J., Chen, C., Tang, H.-Y., Speicher, D.W., and Lieberman, P.M. (2023). Regulation of EBNA1 Protein Stability and DNA Replication Activity by PLOD1 Lysine Hydroxylase. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1010478"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jiang, L., Lan, R., Huang, T., Chan, C.-F., Li, H., Lear, S., Zong, J., Wong, W.-Y., Muk-Lan Lee, M., and Dow Chan, B. (2017). EBNA1-Targeted Probe for the Imaging and Growth Inhibition of Tumours Associated with the Epstein\u2013Barr Virus. Nat. Biomed. Eng., 1.","DOI":"10.1038\/s41551-017-0042"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-Based Design of Small-Molecule Inhibitors of EBNA1 DNA Binding Blocks Epstein-Barr Virus Latent Infection and Tumor Growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","article-title":"First-in-Human Clinical Trial of a Small-Molecule EBNA1 Inhibitor, VK-2019, in Patients with Epstein-Barr\u2013Positive Nasopharyngeal Cancer, with Pharmacokinetic and Pharmacodynamic Studies","volume":"31","author":"Colevas","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","article-title":"Targeted Therapy with Nanatinostat and Valganciclovir in Recurrent EBV-Positive Lymphoid Malignancies: A Phase 1b\/2 Study","volume":"7","author":"Haverkos","year":"2023","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1038\/s41467-024-48031-8","article-title":"Synthetic BZLF1-Targeted Transcriptional Activator for Efficient Lytic Induction Therapy against EBV-Associated Epithelial Cancers","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00795-24","DOI":"10.1128\/mbio.00795-24","article-title":"Targeted Eradication of EBV-Positive Cancer Cells by CRISPR\/DCas9-Mediated EBV Reactivation in Combination with Ganciclovir","volume":"15","author":"Sugiokto","year":"2024","journal-title":"mBio"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13027-019-0246-5","article-title":"CRISPR\/Cas9-Mediated LMP1 Knockout Inhibits Epstein-Barr Virus Infection and Nasopharyngeal Carcinoma Cell Growth","volume":"14","author":"Huo","year":"2019","journal-title":"Infect. Agent. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virusres.2017.04.019","article-title":"Suppression of Epstein-Barr Virus DNA Load in Latently Infected Nasopharyngeal Carcinoma Cells by CRISPR\/Cas9","volume":"244","author":"Yuen","year":"2018","journal-title":"Virus Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yuen, K.-S., Chan, C.-P., Kok, K.-H., and Jin, D.-Y. (2017). Mutagenesis and Genome Engineering of Epstein\u2013Barr Virus in Cultured Human Cells by CRISPR\/Cas9, Springer.","DOI":"10.1007\/978-1-4939-6472-7_2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1099\/jgv.0.000012","article-title":"CRISPR\/Cas9-Mediated Genome Editing of Epstein\u2013Barr Virus in Human Cells","volume":"96","author":"Yuen","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.molcel.2016.12.023","article-title":"Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28","volume":"65","author":"Smargon","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"aaf5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 Is a Single-Component Programmable RNA-Guided RNA-Targeting CRISPR Effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.molcel.2019.09.013","article-title":"Programmable Inhibition and Detection of RNA Viruses Using Cas13","volume":"76","author":"Freije","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Keng, C.T., Yogarajah, T., Lee, R.C.H., Muhammad, I.B.H., Chia, B.S., Vasandani, S.R., Lim, D.S., Guo, K., Wong, Y.H., and Mok, C.K. (2023). AAV-CRISPR-Cas13 Eliminates Human Enterovirus and Prevents Death of Infected Mice. EBioMedicine, 93.","DOI":"10.1016\/j.ebiom.2023.104682"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Huang, Z., Fang, J., Zhou, M., Gong, Z., and Xiang, T. (2022). CRISPR-Cas13: A New Technology for the Rapid Detection of Pathogenic Microorganisms. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1011399"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1373\/clinchem.2018.299347","article-title":"Room Temperature Detection of Plasma Epstein\u2013Barr Virus DNA with CRISPR\u2013Cas13","volume":"65","author":"Wu","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing Real-Time PCR Data by the Comparative CT Method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lui, W.-Y., Bharti, A., Wong, N.-H.M., Jangra, S., Botelho, M.G., Yuen, K.-S., and Jin, D.-Y. (2023). Suppression of CGAS- and RIG-I-Mediated Innate Immune Signaling by Epstein-Barr Virus Deubiquitinase BPLF1. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011186"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F","article-title":"Nasopharyngeal Carcinoma Cell Line (C666-1) Consistently Harbouring Epstein-Barr Virus","volume":"83","author":"Cheung","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/JVI.02104-08","article-title":"Comprehensive Profiling of Epstein-Barr Virus MicroRNAs in Nasopharyngeal Carcinoma","volume":"83","author":"Cosmopoulos","year":"2009","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-9378-8-29","article-title":"Complete Genomic Sequence of Epstein-Barr Virus in Nasopharyngeal Carcinoma Cell Line C666-1","volume":"8","author":"Tso","year":"2013","journal-title":"Infect. Agent. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.cellsig.2010.07.013","article-title":"Epstein\u2013Barr Virus Latent Membrane Protein 1 Increases Chemo-Resistance of Cancer Cells via Cytoplasmic Sequestration of Pim-1","volume":"22","author":"Kim","year":"2010","journal-title":"Cell Signal"},{"key":"ref_35","first-page":"1920","article-title":"Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-Positive Epithelial Cell Tumors","volume":"62","author":"Feng","year":"2002","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1128\/jvi.76.5.2469-2479.2002","article-title":"Epstein-Barr Virus BALF1 Is a BCL-2-Like Antagonist of the Herpesvirus Antiapoptotic BCL-2 Proteins","volume":"76","author":"Bellows","year":"2002","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.27439","article-title":"Activation of Lytic Cycle of Epstein-Barr Virus by Suberoylanilide Hydroxamic Acid Leads to Apoptosis and Tumor Growth Suppression of Nasopharyngeal Carcinoma","volume":"131","author":"Hui","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of Class I Histone Deacetylases by Romidepsin Potently Induces Epstein-Barr Virus Lytic Cycle and Mediates Enhanced Cell Death with Ganciclovir","volume":"138","author":"Hui","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41587-019-0095-1","article-title":"Increasing the Specificity of CRISPR Systems with Engineered RNA Secondary Structures","volume":"37","author":"Kocak","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1038\/s41467-018-06889-5","article-title":"Establishment and Characterization of New Tumor Xenografts and Cancer Cell Lines from EBV-Positive Nasopharyngeal Carcinoma","volume":"9","author":"Lin","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/JVI.73.4.3154-3161.1999","article-title":"Expression of EBNA-1 MRNA Is Regulated by Cell Cycle during Epstein-Barr Virus Type I Latency","volume":"73","author":"Davenport","year":"1999","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1128\/JVI.73.12.9858-9866.1999","article-title":"Role of the Epstein-Barr Virus Rta Protein in Activation of Distinct Classes of Viral Lytic Cycle Genes","volume":"73","author":"Ragoczy","year":"1999","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Xu, C.L., Ruan, M.Z.C., Mahajan, V.B., and Tsang, S.H. (2019). Viral Delivery Systems for CRISPR. Viruses, 11.","DOI":"10.3390\/v11010028"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2013.134","article-title":"AAV8 Induces Tolerance in Murine Muscle as a Result of Poor APC Transduction, T Cell Exhaustion, and Minimal MHCI Upregulation on Target Cells","volume":"22","author":"Mays","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Basner-Tschakarjan, E., and Mingozzi, F. (2014). Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00350"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.1073\/pnas.93.15.7966","article-title":"The Recombination Signals for Adeno-Associated Virus Site-Specific Integration","volume":"93","author":"Linden","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1073\/pnas.91.21.10039","article-title":"Site-Specific Integration by Adeno-Associated Virus Is Directed by a Cellular DNA Sequence","volume":"91","author":"Giraud","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","article-title":"A Largely Random AAV Integration Profile after LPLD Gene Therapy","volume":"19","author":"Kaeppel","year":"2013","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chuang, Y.-F., Wang, P.-Y., Kumar, S., Lama, S., Lin, F.-L., and Liu, G.-S. (2021). Methods for in Vitro CRISPR\/CasRx-Mediated RNA Editing. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.667879"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR Gene Editing Is Negated by Pre-Existing Immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1128\/JVI.00161-16","article-title":"Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site","volume":"90","author":"Huang","year":"2016","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"155427","DOI":"10.1016\/j.prp.2024.155427","article-title":"EBV-Positive Glycoproteins Associated with Nasopharyngeal Carcinoma","volume":"260","author":"Zeng","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Thomas, D., Rathinavel, A.K., and Radhakrishnan, P. (2021). Altered Glycosylation in Cancer: A Promising Target for Biomarkers and Therapeutics. Biochim. Biophys. Acta-Rev. Cancer, 1875.","DOI":"10.1016\/j.bbcan.2020.188464"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.virol.2005.11.021","article-title":"SiRNAs against the Epstein Barr Virus Latency Replication Factor, EBNA1, Inhibit Its Function and Growth of EBV-Dependent Tumor Cells","volume":"346","author":"Yin","year":"2006","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-005-0036-x","article-title":"Suppression of Epstein-Barr Nuclear Antigen 1 (EBNA1) by RNA Interference Inhibits Proliferation of EBV-Positive Burkitt\u2019s Lymphoma Cells","volume":"132","author":"Hong","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_56","first-page":"2286","article-title":"Lentivirus-Mediated RNA Interference Targeting EBNA1 Gene Inhibits the Growth of GT-38 Cells in Vitro and in Vivo","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e14039","DOI":"10.1111\/eci.14039","article-title":"Small Interference (RNAi) Technique: Exploring Its Clinical Applications, Benefits and Limitations","volume":"53","author":"Redhwan","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/gt.2013.76","article-title":"ShRNA-Induced Saturation of the MicroRNA Pathway in the Rat Brain","volume":"21","author":"Sanders","year":"2014","journal-title":"Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"van Diemen, F.R., Kruse, E.M., Hooykaas, M.J.G., Bruggeling, C.E., Sch\u00fcrch, A.C., van Ham, P.M., Imhof, S.M., Nijhuis, M., Wiertz, E.J.H.J., and Lebbink, R.J. (2016). CRISPR\/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005701"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13267","DOI":"10.1128\/JVI.77.24.13267-13274.2003","article-title":"Lytic Viral Replication as a Contributor to the Detection of Epstein-Barr Virus in Breast Cancer","volume":"77","author":"Huang","year":"2003","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lun, S.W.-M., Cheung, S.T., Cheung, P.F.Y., To, K.-F., Woo, J.K.-S., Choy, K.-W., Chow, C., Cheung, C.C.-M., Chung, G.T.-Y., and Cheng, A.S.-H. (2012). CD44+ Cancer Stem-Like Cells in EBV-Associated Nasopharyngeal Carcinoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0052426"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A Multifunctional AAV-CRISPR-Cas9 and Its Host Response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199805143382002","article-title":"The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children","volume":"338","author":"Belshe","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2045853","DOI":"10.1080\/21645515.2022.2045853","article-title":"COVID-19 Intranasal Vaccines: Current Progress, Advantages, Prospects, and Challenges","volume":"18","author":"Dhama","year":"2022","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/899\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:59Z","timestamp":1760032739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":64,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["v17070899"],"URL":"https:\/\/doi.org\/10.3390\/v17070899","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}